Clinical Trials Directory

Trials / Completed

CompletedNCT05059691

Three-Dimensional Fluoroscopic Guidance During Transbronchial Cryobiopsy

Three-Dimensional Fluoroscopic Guidance During Transbronchial Cryobiopsy, a Prospective Pilot Study

Status
Completed
Phase
Study type
Observational
Enrollment
5 (actual)
Sponsor
M.D. Anderson Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study assesses the effectiveness of transbronchial cryobiopsy guided by 3-dimensional fluoroscopy. Transbronchial cryobiopsy is a procedure to collect lung tissue. The main side effect seen after a transbronchial cryobiopsy is pneumothorax (air leaking out of the lung, which may cause a completely or partially collapsed lung). The standard imaging scans used during this procedure are 2-dimensional (like a photo), which can make it difficult for the doctor to know exactly where the biopsy tool is during the procedure. If the exact location of the device is not clear, a patient can be at a higher risk of pneumothorax. Using a 3-dimensional imaging technique may help to decrease the risk of pneumothorax during transbronchial cryobiopsy.

Detailed description

PRIMARY OBJECTIVE: I. To determine if transbronchial cryobiopsy guided by three-dimensional fluoroscopy reduces the incidence of pneumothorax up to 72 hours after transbronchial cryobiopsy. SECONDARY OBJECTIVE: I. To describe outcomes of cryobiopsy, need for interventions related to transbronchial cryobiopsy, radiation dose, and any complications or adverse events after transbronchial cryobiopsy guided by three-dimensional fluoroscopy. OUTLINE: Patients undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy. Patients' medical records are also reviewed.

Conditions

Interventions

TypeNameDescription
OTHERElectronic Health Record ReviewReview of medical records
PROCEDURETransbronchial Cryobiopsy Guided by Three-Dimensional FluoroscopyUndergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy

Timeline

Start date
2021-03-30
Primary completion
2023-05-11
Completion
2023-05-11
First posted
2021-09-28
Last updated
2023-05-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05059691. Inclusion in this directory is not an endorsement.